DESIGN OF ANIFROLUMAB STUDY OF TREATMENT EFFECTIVENESS IN THE REAL WORLD (ASTER): A MULTI-NATIONAL, OBSERVATIONAL, POST-LAUNCH STUDY TO DESCRIBE THE CLINICAL EFFECTIVENESS OF ANIFROLUMAB IN ROUTINE CLINICAL PRACTICE IN PATIENTS WITH SLE

被引：0

作者：

Mosca, M. ^{[1
]}

Emmas, C. ^{[2
]}

Nan, C. ^{[3
]}

Stirnadel-Farrant, H. ^{[4
]}

Chen, S. ^{[5
,9
]}

Carty, L. ^{[6
]}

Desta, B. ^{[7
]}

Seo, C. ^{[8
]}

Chen, S. ^{[5
,9
]}

Sorrentino, A. ^{[10
]}

机构：

[1] Univ Pisa, Clin & Expt Med, Pisa, Italy

[2] AstraZeneca, Resp Immunol Evidence, Biopharmaceut Med, Cambridge, England

[3] AstraZeneca, CVRM Evidence, Biopharmaceut Med, Molndal, Sweden

[4] AstraZeneca, Oncol Outcomes Res, Global Med Affairs, Cambridge, England

[5] AstraZeneca, Evidence Delivery, Biopharmaceut Med, Molndal, Sweden

[6] AstraZeneca, Biostat, Cambridge, England

[7] AstraZeneca, Biopharmaceut Business Unit, Gaithersburg, MD USA

[8] AstraZeneca, Patient Centered Sci, Biopharmaceut Med Evidence, Gaithersburg, MD USA

[9] AstraZeneca, BioPharmaceut Med, Gaithersburg, MD USA

[10] AstraZeneca, Global Med Affairs Resp & Immunol, BioPharmaceut Med, Cambridge, England

来源：

关键词：

Real-world evidence; Quality of life; Systemic lupus erythematosus;

D O I：

10.1136/annrheumdis-2023-eular.1566

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB0546

引用

页码：1471 / 1472

页数：2